Felix Scheuplein

Felix Scheuplein

Auto-generated profile, based on publicly available information

Felix Scheuplein

Institute of Immunology, University Hospital, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2009 in Medical Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
JWJanusz Wesolowski
Janusz Wesolowski
VAVanina Alzogaray
Vanina Alzogaray
JRJan Reyelt
Jan Reyelt
MUMandy Unger
Mandy Unger
Karla Juarez-MorenoKarla Juarez-Moreno
Karla Juarez-Moreno
FKFriedrich Koch-Nolte
Friedrich Koch-Nolte
Antibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.

1 October 2003 in Immunity
Verified
Journal Article
Closed access
MSMichel Seman
Michel Seman
SASahil Adriouch
Sahil Adriouch
FSFelix Scheuplein
Felix Scheuplein
CKChristian Krebs
Christian Krebs
DFDunja Freese
Dunja Freese
FKFriedrich Koch-Nolte
Friedrich Koch-Nolte

9 January 2007 in Purinergic Signalling
Verified
Journal Article
Open access
PDF file
Friedrich HaagFriedrich Haag
Friedrich Haag
SASahil Adriouch
Sahil Adriouch
ABAnette Braß
Anette Braß
CJCaroline Jung
Caroline Jung
SMSina Möller
Sina Möller
FKFriedrich Koch-Nolte
Friedrich Koch-Nolte
Extracellular NAD and ATP exert multiple, partially overlapping effects on immune cells. Catabolism of both nucleotides by extracellular enzymes keeps extracellular concentrations low under steady-state conditions and generates metabolites that are themselves signal transducers. ATP and its metabolites signal through purinergic P2 and P1 receptors, whereas extracellular NAD exerts its effects by serving as a substrate for ADP-ribosyltransferases (ARTs) and NAD glycohydrolases/ADPR cyclases like CD38 and CD157. Both nucleotides activate the P2X7 purinoceptor, although by different mechanisms and with different characteristics. While ATP activates P2X7 directly as a soluble ligand, activation via NAD occurs by ART-dependent ADP-ribosylation of cell surface proteins, providing an immobilised ligand. P2X7 activation by either route leads to phosphatidylserine exposure, shedding of CD62L, and ultimately to cell death. Activation by ATP requires high micromolar concentrations of nucleotide and is readily reversible, whereas NAD-dependent stimulation begins at low micromolar concentrations and is more stable. Under conditions of cell stress or inflammation, ATP and NAD are released into the extracellular space from intracellular stores by lytic and non-lytic mechanisms, and may serve as ‘danger signals–to alert the immune response to tissue damage. Since ART expression is limited to naïve/resting T cells, P2X7-mediated NAD-induced cell death (NICD) specifically targets this cell population. In inflamed tissue, NICD may inhibit bystander activation of unprimed T cells, reducing the risk of autoimmunity. In draining lymph nodes, NICD may eliminate regulatory T cells or provide space for the preferential expansion of primed cells, and thus help to augment an immune response.

1 March 2009 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
FSFelix Scheuplein
Felix Scheuplein
NSNicole Schwarz
Nicole Schwarz
SASahil Adriouch
Sahil Adriouch
CKChristian Krebs
Christian Krebs
PBPeter Bannas
Peter Bannas
FKFriedrich Koch-Nolte
Friedrich Koch-Nolte
Extracellular NAD+ and ATP trigger the shedding of CD62L and the externalization of phosphatidylserine on murine T cells. These events depend on the P2X7 ion channel. Although ATP acts as a soluble ligand to activate P2X7, gating of P2X7 by NAD+ requires ecto-ADP-ribosyltransferase ART2.2-catalyzed transfer of the ADP-ribose moiety from NAD+ onto Arg125 of P2X7. Steady-state concentrations of NAD+ and ATP in extracellular compartments are highly regulated and usually are well below the threshold required for activating P2X7. The goal of this study was to identify possible endogenous sources of these nucleotides. We show that lysis of erythrocytes releases sufficient levels of NAD+ and ATP to induce activation of P2X7. Dilution of erythrocyte lysates or incubation of lysates at 37°C revealed that signaling by ATP fades more rapidly than that by NAD+. We further show that the routine preparation of primary lymph node and spleen cells induces the release of NAD+ in sufficient concentrations for ART2.2 to ADP-ribosylate P2X7, even at 4°C. Gating of P2X7 occurs when T cells are returned to 37°C, rapidly inducing CD62L-shedding and PS-externalization by a substantial fraction of the cells. The “spontaneous” activation of P2X7 during preparation of primary T cells could be prevented by i.v. injection of either the surrogate ART substrate etheno-NAD or ART2.2-inhibitory single domain Abs 10 min before sacrificing mice.

15 June 2007 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
FKFriedrich Koch-Nolte
Friedrich Koch-Nolte
JRJan Reyelt
Jan Reyelt
BSBritta Schößow
Britta Schößow
NSNicole Schwarz
Nicole Schwarz
FSFelix Scheuplein
Felix Scheuplein
FGFernando Alberto Goldbaum
Fernando Alberto Goldbaum

1 April 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
YCYi-Guang Chen
Yi-Guang Chen
FSFelix Scheuplein
Felix Scheuplein
JDJohn P. Driver
John P. Driver
AHAmanda A Hewes
Amanda A Hewes
PRPeter C. Reifsnyder
Peter C. Reifsnyder
DSDavid V. Serreze
David V. Serreze
Although P2rx7 has been proposed as a type 1 diabetes (T1D) susceptibility gene in NOD mice, its potential pathogenic role has not been directly determined. To test this possibility, we generated a new NOD stock deficient in P2X7 receptors. T1D development was not altered by P2X7 ablation. Previous studies found CD38 knockout (KO) NOD mice developed accelerated T1D partly because of a loss of CD4+ invariant NKT (iNKT) cells and Foxp3+ regulatory T cells (Tregs). These immunoregulatory T cell populations are highly sensitive to NAD-induced cell death activated by ADP ribosyltransferase-2 (ART2)-mediated ADP ribosylation of P2X7 receptors. Therefore, we asked whether T1D acceleration was suppressed in a double-KO NOD stock lacking both P2X7 and CD38 by rescuing CD4+ iNKT cells and Tregs from NAD-induced cell death. We demonstrated that P2X7 was required for T1D acceleration induced by CD38 deficiency. The CD38 KO-induced defects in homeostasis of CD4+ iNKT cells and Tregs were corrected by coablation of P2X7. T1D acceleration in CD38-deficient NOD mice also requires ART2 expression. If increased ADP ribosylation of P2X7 in CD38-deficient NOD mice underlies disease acceleration, then a comparable T1D incidence should be induced by coablation of both CD38 and ART2, or CD38 and P2X7. However, a previously established NOD stock deficient in both CD38 and ART2 expression is T1D resistant. This study demonstrated the presence of a T1D resistance gene closely linked to the ablated Cd38 allele in the previously reported NOD stock also lacking ART2, but not in the newly generated CD38/P2X7 double-KO line.